Supplemental table 3
Cox regression in subgroups
validation cohort

Characteristic	PFS				OS			
	N	HR[1]	95% CI[1]	p-value	N	HR[1]	95% CI[1]	p-value
concurrent chemotherapy								
ICB monotherapy	84				84			
Non-Responder		—	—			—	—	
Responder		0.30	0.16, 0.55	**<0.001**		0.39	0.22, 0.69	**0.001**
Flare-Responder		0.22	0.10, 0.45	**<0.001**		0.31	0.16, 0.60	**<0.001**
concurrent chemotherapy	23				23			
Non-Responder		—	—			—	—	
Responder		1.09	0.24, 4.89	>0.9		0.56	0.19, 1.61	0.3
Flare-Responder		0.51	0.09, 3.07	0.5		0.39	0.11, 1.37	0.14
line of therapy								
first line	42				42			
Non-Responder		—	—			—	—	
Responder		0.45	0.17, 1.24	0.12		0.32	0.14, 0.73	**0.007**
Flare-Responder		0.11	0.02, 0.53	**0.006**		0.13	0.04, 0.42	**<0.001**
higher lines	65				65			
Non-Responder		—	—			—	—	
Responder		0.34	0.17, 0.67	**0.002**		0.49	0.26, 0.92	**0.028**
Flare-Responder		0.34	0.16, 0.72	**0.005**		0.47	0.24, 0.93	**0.031**
concurrent steroid medication								
no concurrent steroid medication	90				90			
Non-Responder		—	—			—	—	
Responder		0.32	0.17, 0.61	**<0.001**		0.39	0.23, 0.68	**<0.001**
Flare-Responder		0.20	0.09, 0.44	**<0.001**		0.30	0.16, 0.57	**<0.001**
concurrent steroid medication	17				17			
Non-Responder		—	—			—	—	
Responder		0.89	0.24, 3.34	0.9		0.76	0.23, 2.53	0.7
Flare-Responder		0.48	0.12, 2.04	0.3		0.36	0.09, 1.46	0.2

[1] HR = Hazard Ratio, CI = Confidence Interval